Northwest Biotherapeutics (OTCMKTS:NWBO) and Structure Therapeutics (NASDAQ:GPCR) Critical Survey

Northwest Biotherapeutics (OTCMKTS:NWBO) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Northwest Biotherapeutics and Structure Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Northwest Biotherapeutics	0	0	0	0	0.00
Structure Therapeutics	2	1	13	3	2.89

Structure Therapeutics has a consensus price target of $106.75, suggesting a potential upside of 148.66%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Northwest Biotherapeutics.

Risk and Volatility

Northwest Biotherapeutics has a beta of -0.67, meaning that its stock price is 167% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.35, meaning that its stock price is 235% less volatile than the S&P 500.

Profitability

This table compares Northwest Biotherapeutics and Structure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northwest Biotherapeutics	-2,931.73%	N/A	-79.26%
Structure Therapeutics	N/A	-24.91%	-23.67%

Earnings & Valuation

This table compares Northwest Biotherapeutics and Structure Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northwest Biotherapeutics	$1.38 million	243.30	-$60.16 million	($18.23)	-0.01
Structure Therapeutics	N/A	N/A	-$141.20 million	($0.87)	-49.34

Northwest Biotherapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.0% of Northwest Biotherapeutics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 2.4% of Northwest Biotherapeutics shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Structure Therapeutics beats Northwest Biotherapeutics on 9 of the 14 factors compared between the two stocks.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.